# 858 Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/858-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.8five8tx.com
- Total disclosed funding: $85M
- Latest round: Series B (Jun 26, 2024)
- Investors on record: 8

## About

Based in California, US, and founded in 2019, 858 Therapeutics, Inc. operates as a biotechnology company that develops small molecules directed against therapeutic targets in oncology, including proteins that control Ribonucleic acid and the immune response. In September 2024, 858 Therapeutics, Inc. raised USD 50 million in series B funding led by new investor Avidity Partners, with participation from other new investors Insight Equity Partners, Mirae Asset Capital, and Alexandria Venture Investments. Returning investors Versant Ventures, New Enterprise Associates, and Logos Capital also participated in the round.

858 Therapeutics built a platform that focuses on Ribonucleic acid (RNA) metabolism and immune sensing mechanisms to discover small-molecule therapeutics for the treatment of cancer. The platform includes a suite of proprietary in vitro biochemical and biophysical assays, as well as cellular assays.

858 Therapeutics plans to enter the clinic with its lead products that have the potential to treat cancers that are resistant to current therapies and expand its team to about 40 people within the next 18 months. It also plans to bring leading academic scientists with specialization in the field to contribute to the company.

## Funding rounds

- Series B, Jun 26, 2024, $25M — New Enterprise Associates, Versant Ventures, Alexandria Venture Investments, Logos Capital, Insight Equity Partners, Avidity Partners, Mirae Asset Capital
- Series A, Sep 21, 2021, $60M — New Enterprise Associates, Versant Ventures, Cormorant Asset Management, Logos Capital

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Insight Equity Partners (https://capitalatlas.ai/funds/insight-equity-partners) — Series B
- Avidity Partners — Series B
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series B